Sensex
78,130.77 profit arw 1,283.20 (1.67%)
Nifty
24,229.05 profit arw 386.40 (1.62%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 01-Apr-2026
Hot Pursuit
01-Apr-2026     13:15

Marksans Pharma gains on securing USFDA approval for Benzonatate Capsules

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Tessalon Capsules, 100 mg and 200 mg, marketed by Pfizer Inc.

Benzonatate is a non-narcotic antitussive that works by numbing stretch receptors in the respiratory tract, thereby suppressing the cough reflex. It is commonly used for the symptomatic relief of persistent cough associated with conditions such as bronchitis, pneumonia, and other respiratory infections.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

The company's consolidated net profit increased 8.26% year-on-year to Rs 113.20 crore, despite a 10.64% jump in revenue from operations to Rs 754.42 crore in Q3 FY26 compared with Q3 FY25.

INDIAN INDICES

Sensex

78,130.77 1,283.20 (1.67%)

Nifty

24,229.05 386.40 (1.62%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,872.33 211.47(0.82%)